InTrack Investment Management Inc Lowers Stock Holdings in Zoetis Inc. $ZTS

InTrack Investment Management Inc reduced its position in Zoetis Inc. (NYSE:ZTS) by 10.3% in the 2nd quarter, Holdings Channel reports. The fund owned 4,369 shares of the company’s stock after selling 501 shares during the period. InTrack Investment Management Inc’s holdings in Zoetis were worth $681,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nova Wealth Management Inc. purchased a new stake in Zoetis in the 1st quarter worth approximately $25,000. 1248 Management LLC acquired a new position in shares of Zoetis in the 1st quarter valued at $27,000. Saudi Central Bank acquired a new position in shares of Zoetis in the 1st quarter valued at $29,000. Cornerstone Planning Group LLC boosted its holdings in shares of Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after purchasing an additional 88 shares during the last quarter. Finally, REAP Financial Group LLC boosted its holdings in shares of Zoetis by 201.5% in the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after purchasing an additional 131 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

ZTS opened at $143.61 on Thursday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The company has a 50-day moving average of $149.41 and a 200-day moving average of $154.74. The company has a market capitalization of $63.65 billion, a P/E ratio of 24.72, a PEG ratio of 2.29 and a beta of 0.90. Zoetis Inc. has a 1-year low of $139.34 and a 1-year high of $196.55.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis’s revenue was up 4.2% on a year-over-year basis. During the same period in the previous year, the business posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of research analyst reports. Piper Sandler lifted their price target on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday. Argus restated a “buy” rating and set a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Finally, Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Five analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.